Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy
Mrinal M Patnaik1, Tariq I Mughal2,3, Christopher Brooks3
1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Leukemia & Lymphoma
|May 17, 2021
Summary
Targeting interleukin 3 receptor α chain (IL-3Rα; CD123) on leukemia stem cells (LSCs) shows promise for myeloid malignancies. Identifying patients who benefit from CD123-targeted therapies requires understanding expression patterns and clinical impact.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Interleukin 3 receptor α chain (IL-3Rα; CD123) is upregulated on leukemia stem cells (LSCs).
- Targeted therapies using CD123-diphtheria toxin conjugates have been investigated for myeloid malignancies.
- Limited success of current CD123-targeted therapies necessitates better patient selection criteria.
Purpose of the Study:
- To review methodologies for assessing CD123 expression.
- To discuss biological and clinical characteristics of patients who may benefit from CD123-targeting therapies.
- To understand CD123 expression patterns and their pathogenetic significance in hematologic malignancies.
Main Methods:
- Review of existing literature on CD123 assessment methodologies.
- Analysis of biological and clinical data related to CD123 expression in hematologic malignancies.
- Discussion of the functional significance of CD123 in disease pathogenesis.
Main Results:
- CD123 expression varies across different hematologic malignancies.
- Understanding CD123 expression patterns is crucial for effective targeted therapy.
- Patient selection criteria are needed to optimize CD123-targeted treatment outcomes.
Conclusions:
- CD123-targeted therapies offer a potential strategy for treating hematologic malignancies.
- Further research is needed to refine patient selection for CD123-targeted treatments.
- Comprehensive understanding of CD123 biology and expression is key to clinical success.
